Breast Cancer Therapeutics in Asia-Pacific Markets to 2024
Asia-Pacific (APAC) breast cancer market was valued at $2.16
billion in 2017, and is expected to grow at a compound annual growth rate
(CAGR) of 11.9% to reach $4.75 billion in 2024.
The major factors that are expected to drive the market
include increases in diagnosed prevalence and the annual cost of therapy (ACoT)
due to higher uptake of costlier therapies. Older women are at a higher risk of
developing breast cancer. The aging population, changing lifestyle habits and
improved survival rates will increase the prevalence of breast cancer and be
the driving factors underlying the forecast market growth. Additionally, the
implementation of nationwide breast cancer screening programs in Asia-Pacific
will contribute to an increase in the diagnosis of early-stage disease.
Breast cancer is not a single disease, but rather a group of
several different tumor subtypes. Although many subtypes exist, they are
generally categorized by the presence or absence of the ER, PR, and HER2.
Broadly, patients can be segmented into two types: the human epidermal growth
factor receptor (HER)2-negative segment and the HER2-positive segment.
HER2-negative breast cancer is the most common type and is usually diagnosed in